Hledání v detailu akcií
Moje portfolio
Nastavit Oblíbené, nastavit Portfolio
Oblíbené tituly
select
NázevNejlepší
nákup
Nejlepší
prodej
Změna
(%)
ČEZ0,00
KB0,00
PKN85,0285,1-0,99
Msft-0,40
Nokia4,3554,4990,53
IBM-0,93
Mercedes-Benz Group AG53,0653,081,63
PFE0,86
11.07.2025 1:12:40
Indexy online
AD Index online
select
AD Index online
 

  • 10.07.2025 22:00:00
BioNTech Sp ADS (NASDAQ Cons)
Poslední obchod Změna (%) Změna (USD) Objem obchodů (ks)
113,92 1,91 2,14 649 025
After-hours11.07.2025 0:10:11
Poslední obchod Nákup / Prodej Změna (%) Změna (USD)
113,90 - - 1,91 2,14
R - Real-Time data si mohou aktivovat klienti Patria Plus / Investor Plus ZDE.

 
  • Poslední aktualizace: 11.07.2025
Popis společnosti

Business Summary: BioNTech SE is a Germany-based clinical-stage biotechnology company. The Company focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. The Company is providing technologies including mRNA-based therapies, cell therapies, small molecules and antibodies, which can be utilized for specific purposes or can be even combined with each other in a synergistic manner. It also develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules. In addition, the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders.
Financial Summary: BRIEF: For the nine months ended 30 September 2024, BioNTech SE - ADR revenues decreased 33% to EUR1.56B. Net loss totaled EUR924.8M vs. income of EUR472.4M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Net loss reflects Gain on derivative instruments at fair v decrease of 92% to EUR5.7M (income), Loss on derivative instruments at fair v increase from EUR0K to EUR31.9M (expense).



  • Poslední aktualizace: 11.07.2025
Management společnosti
FunkceJménoVěkVe funkci odVe firmě od
Chief Executive Officer, DirectorTimothy Cook6424.08.2011
Senior Vice President, Chief Financial OfficerKevan Parekh5301.01.202501.01.2025
Chief Operating OfficerJeffrey Williams6113.11.2018
Senior Vice President, General Counsel, SecretaryKatherine Adams6013.11.201713.11.2017
Senior Vice President - Retail and PeopleDeirdre O'Brien5805.02.201905.02.2019